DOT Cannabis Testing Policy: Federal Rules for Safety-Sensitive Jobs

Executive Summary

The U.S. Department of Transportation maintains strict cannabis testing requirements for safety-sensitive transportation workers despite evolving federal cannabis policy and state-level legalization. DOT-regulated employers must continue testing approximately 13 million transportation workers for marijuana under 49 CFR Part 40, regardless of state medical or recreational cannabis laws. The policy affects commercial drivers, pilots, railroad employees, transit operators, pipeline workers, and maritime crew members. Recent tension between DOT enforcement and White House cannabis reform initiatives has created regulatory uncertainty for employers and workers across the transportation sector. With cannabis rescheduling under consideration and state legalization expanding to 38 states as of 2026, the collision between federal workplace safety mandates and cannabis normalization represents one of the most consequential policy conflicts in American drug testing history.

Why This Matters

DOT cannabis testing policy directly impacts 13 million American workers and thousands of transportation employers navigating conflicting federal and state laws. The stakes extend far beyond individual employment decisions. Transportation safety depends on impairment-free operation of commercial vehicles, aircraft, trains, and pipelines. A single impaired operator can cause catastrophic accidents affecting hundreds of lives. The economic implications are substantial. The American Trucking Associations reported in 2025 that the industry faces a shortage of 78,000 drivers, with failed drug tests contributing significantly to recruitment challenges. Approximately 50,000 CDL applicants fail pre-employment drug screens annually, with marijuana accounting for roughly 60% of positive tests according to Federal Motor Carrier Safety Administration data. For workers, the policy creates impossible choices. Medical cannabis patients with valid state authorizations face career barriers in transportation. A Colorado truck driver using state-legal CBD oil for chronic pain risks federal disqualification. A California pilot prescribed medical marijuana for PTSD cannot legally fly commercial aircraft regardless of state law. Employers face compliance complexity and legal exposure. Transportation companies must navigate 38 different state cannabis laws while maintaining federal DOT compliance. The cost of non-compliance is severe: civil penalties up to $500,000, loss of operating authority, and personal liability for company officials under 49 U.S.C. § 521(b)(2)(C). The policy also intersects with social equity concerns. Cannabis prohibition has disproportionately impacted communities of color. DOT testing perpetuates employment barriers even as states expunge cannabis convictions and promote equity in legalization programs.

Background and History

DOT cannabis testing emerged from the 1980s War on Drugs and evolved through three decades of regulatory expansion, technological advancement, and collision with state legalization movements.

Origins: The Drug-Free Workplace Act Era (1986-1991)

Federal workplace drug testing began with Executive Order 12564, signed by President Reagan on September 15, 1986. The order declared the federal government's goal of achieving a "drug-free workplace" and authorized drug testing for federal employees in safety-sensitive positions. The Drug-Free Workplace Act of 1988 extended requirements to federal contractors. The Omnibus Transportation Employee Testing Act of 1991 created the modern DOT testing framework. Congress mandated that the Secretary of Transportation establish testing programs for safety-sensitive employees in aviation, motor carrier, railroad, mass transit, pipeline, and maritime industries. The legislation responded to high-profile accidents where substance use was a contributing factor, including the 1987 Conrail-Amtrak collision that killed 16 people and injured 176.

Regulatory Implementation (1991-1995)

DOT published its first comprehensive drug testing regulations on December 1, 1994, effective January 1, 1995. The rules established 49 CFR Part 40 as the master framework governing all DOT agency testing programs. Part 40 specified five-panel urine testing for marijuana, cocaine, amphetamines, opiates, and phencyclidine (PCP). The regulations defined marijuana testing parameters: initial immunoassay screening at 50 ng/mL THC-COOH, with gas chromatography/mass spectrometry (GC/MS) confirmation at 15 ng/mL. These thresholds remain unchanged as of 2026, despite advances in testing technology and changes in cannabis potency. Each DOT operating administration published mode-specific regulations: Federal Aviation Administration (14 CFR Part 120), Federal Motor Carrier Safety Administration (49 CFR Part 382), Federal Railroad Administration (49 CFR Part 219), Federal Transit Administration (49 CFR Part 655), Pipeline and Hazardous Materials Safety Administration (49 CFR Part 199), and U.S. Coast Guard (46 CFR Part 16).

Medical Marijuana Collision (1996-2012)

California's Proposition 215 in 1996 created the first state medical marijuana program, initiating a 30-year conflict between state and federal cannabis policy. DOT immediately clarified that state medical marijuana laws provided no exception to federal testing requirements. In 2008, DOT issued a formal notice stating that transportation employees who test positive for marijuana remain in violation of DOT regulations "even if the employee has a state-authorized medical marijuana card or prescription." The notice cited the Controlled Substances Act's Schedule I classification of marijuana under 21 U.S.C. § 812, which defines marijuana as having no accepted medical use under federal law. The 2009 Ogden Memorandum from Deputy Attorney General David Ogden deprioritized federal prosecution of state-compliant medical marijuana patients, but DOT explicitly stated the memo did not apply to transportation safety regulations.

Recreational Legalization and Regulatory Tension (2012-2020)

Colorado and Washington became the first states to legalize recreational cannabis in November 2012. DOT responded with a December 2012 notice reaffirming that state marijuana laws "do not change the Department of Transportation's drug testing requirements." The Federal Motor Carrier Safety Administration issued guidance in 2014 addressing employer questions about state legalization. FMCSA emphasized that motor carriers must continue testing for marijuana and disqualifying drivers who test positive, regardless of state law. The guidance noted that 49 CFR § 382.107 explicitly prohibits carriers from allowing drivers to use marijuana. By 2020, 33 states had legalized medical marijuana and 11 had legalized recreational use. DOT maintained its position without modification. Administrator Jim Mullen of FMCSA stated in 2019 Congressional testimony that "marijuana remains a drug of concern for highway safety" and that federal testing requirements would continue unchanged.

CBD and Hemp Complications (2018-2024)

The Agriculture Improvement Act of 2018 (Farm Bill) legalized hemp containing less than 0.3% THC and removed it from Schedule I. The law created widespread confusion about CBD products and DOT testing. DOT issued a November 2019 notice warning transportation employees that CBD products could cause positive marijuana tests. The notice stated that DOT "has no role in approving, certifying, or listing products that claim to contain CBD" and that employees who test positive for marijuana face consequences regardless of CBD use claims. The Federal Aviation Administration published a 2020 information bulletin prohibiting pilots and air traffic controllers from using CBD products, stating that "the use of hemp-derived CBD can result in a positive drug test" and that "the FAA will not accept the use of CBD products as a legitimate medical explanation for a positive drug test." Testing data confirmed DOT's concerns. Quest Diagnostics reported in 2023 that CBD product use contributed to a 16% increase in positive marijuana tests among safety-sensitive workers between 2020 and 2023.

Rescheduling Debate and Current Tensions (2024-2026)

The Biden administration initiated a comprehensive review of marijuana scheduling in October 2022. The Department of Health and Human Services recommended in August 2023 that DEA reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act. DEA published a Notice of Proposed Rulemaking on May 16, 2024, proposing to reschedule marijuana to Schedule III. The proposal acknowledged marijuana's accepted medical use but maintained federal control. Public comment period extended through July 2024, with over 43,000 submissions received. DOT issued a statement in June 2024 clarifying that rescheduling to Schedule III would not automatically change DOT testing requirements. The statement noted that 49 CFR Part 40 specifically lists marijuana as a tested substance, independent of its CSA schedule. Regulatory changes would require separate DOT rulemaking. The May 2026 news report indicating DOT is "bucking the President" on cannabis reflects this ongoing tension. While the White House has signaled support for cannabis reform, DOT has maintained that transportation safety mandates require continued testing regardless of broader policy shifts.

Key Players

Department of Transportation

DOT's Office of Drug and Alcohol Policy and Compliance administers the federal testing program affecting 13 million workers. The office, led by Director Patrice Kelley as of 2026, interprets 49 CFR Part 40 and coordinates with six operating administrations. DOT's position emphasizes that transportation safety is non-negotiable and that marijuana impairment poses unacceptable risks regardless of state legalization trends.

Federal Motor Carrier Safety Administration

FMCSA regulates approximately 3.5 million commercial drivers. The agency maintains the Drug and Alcohol Clearinghouse, a database launched January 6, 2020, that tracks CDL holders who fail drug tests or refuse testing. As of March 2026, the Clearinghouse contained over 175,000 records of marijuana violations. FMCSA Administrator Robin Hutcheson has stated that marijuana remains the "number one drug of concern" for highway safety.

Federal Aviation Administration

FAA regulates pilots, air traffic controllers, flight attendants, and aviation maintenance workers. The agency maintains the most restrictive cannabis policy among DOT modes. FAA's Office of Aerospace Medicine prohibits any marijuana use and does not recognize state medical marijuana authorizations. Federal Air Surgeon Dr. Susan Northrup has emphasized that "aviation safety requires zero tolerance for impairing substances."

Federal Railroad Administration

FRA regulates approximately 130,000 railroad workers. The agency implemented post-accident testing requirements after the 1987 Chase, Maryland collision where the Conrail engineer tested positive for marijuana. FRA's Part 219 regulations include random testing at 25% annual rate and post-accident testing for all crew members involved in qualifying incidents.

Commercial Driver Advocacy Groups

The Owner-Operator Independent Drivers Association represents 150,000 truckers and has called for DOT to reconsider marijuana testing policies in light of state legalization. OOIDA President Todd Spencer said in 2025 testimony that "drivers are being disqualified for off-duty conduct that is legal in their home states, exacerbating the driver shortage." The organization supports impairment-based testing rather than metabolite detection.

Transportation Employers

The American Trucking Associations, Airlines for America, and American Public Transportation Association support continued DOT testing requirements. These groups emphasize safety concerns and liability exposure. ATA President Chris Spear stated in 2024 that "until we have reliable roadside impairment testing, we must maintain current protocols to protect the traveling public."

Drug Testing Industry

Quest Diagnostics, LabCorp, and other testing laboratories process millions of DOT specimens annually. The industry has invested in developing oral fluid testing technology as an alternative to urine testing. Quest's 2025 Drug Testing Index reported that marijuana positivity rates among DOT-regulated workers reached 1.7%, the highest level since 2008.

Cannabis Industry and Reform Advocates

The National Organization for the Reform of Marijuana Laws and Drug Policy Alliance advocate for ending workplace cannabis testing. NORML Deputy Director Paul Armentano argues that "testing for inactive marijuana metabolites that can persist for weeks bears no relationship to workplace impairment or safety." These groups support impairment-based testing using cognitive assessments rather than drug metabolite detection.

Legal and Regulatory Framework

DOT cannabis testing authority derives from multiple federal statutes, with 49 CFR Part 40 serving as the master regulation governing testing procedures across all transportation modes. The Omnibus Transportation Employee Testing Act of 1991, codified at 49 U.S.C. § 20140 (rail), 49 U.S.C. § 31306 (motor carrier), and 49 U.S.C. § 45102 (aviation), mandates that DOT establish testing programs. The statute requires testing for marijuana and authorizes the Secretary of Transportation to establish testing procedures, frequency, and consequences. 49 CFR Part 40, revised most recently in 2023, establishes uniform procedures for all DOT drug testing. Subpart A defines marijuana as "all cannabis derivatives containing greater than 0.3% delta-9-tetrahydrocannabinol." Part 40 specifies collection procedures, laboratory certification requirements, Medical Review Officer protocols, and return-to-duty processes. Each operating administration maintains mode-specific regulations that incorporate Part 40 by reference: 49 CFR Part 382 governs motor carrier testing. Section 382.107 prohibits motor carriers from allowing drivers to use marijuana. Section 382.305 requires random testing at 50% annual rate (increased from 25% in 2020). Section 382.213 mandates pre-employment testing for all CDL drivers. 14 CFR Part 120 governs aviation testing. The regulation covers pilots, flight attendants, flight instructors, aircraft dispatchers, maintenance personnel, ground security coordinators, and air traffic controllers. Random testing occurs at 25% annual rate for flight crew members and 10% for other employees. 49 CFR Part 219 governs railroad testing. Subpart C requires post-accident toxicological testing for all crew members involved in accidents meeting specified criteria. Subpart G establishes random testing at 25% annual rate. 49 CFR Part 655 governs transit testing. The regulation applies to safety-sensitive transit employees including bus drivers, rail operators, mechanics, and dispatchers. Random testing occurs at 50% annual rate. The Controlled Substances Act, 21 U.S.C. § 812, classifies marijuana as Schedule I, defining it as having high abuse potential and no accepted medical use. This classification provides the legal foundation for DOT's position that state medical marijuana laws do not override federal testing requirements. Federal preemption doctrine, established in the Supremacy Clause of Article VI of the U.S. Constitution, gives federal law priority over conflicting state laws. Courts have consistently held that DOT testing requirements preempt state cannabis laws in the transportation context. In Beinor v. Industrial Commission of Arizona (2020), the Arizona Court of Appeals held that a commercial driver could be terminated for medical marijuana use despite state law protections, because federal DOT regulations preempted state employment protections. The court noted that 49 U.S.C. § 31306(b)(1)(A) explicitly requires motor carriers to test for marijuana. The Americans with Disabilities Act, 42 U.S.C. § 12114(a), explicitly excludes current illegal drug use from disability protections. Because marijuana remains federally illegal, ADA does not require employers to accommodate medical marijuana use. The Equal Employment Opportunity Commission confirmed this interpretation in 2020 guidance.

State-by-State Impact

DOT testing requirements apply uniformly across all states, but the practical impact varies significantly based on state cannabis laws and workforce composition.

California

California legalized recreational cannabis in 2016 and has the nation's largest transportation workforce. Approximately 1.2 million Californians work in DOT-regulated positions. The state's Compassionate Use Act of 1996 and Adult Use of Marijuana Act provide no protection for transportation workers. California courts have held that employers can terminate employees for off-duty marijuana use when required by federal law. The California Supreme Court ruled in Ross v. RagingWire Telecommunications (2008) that the Compassionate Use Act does not require employers to accommodate medical marijuana use.

Colorado

Colorado legalized recreational cannabis in 2012. The state has approximately 285,000 DOT-regulated workers, including significant numbers in trucking and pipeline operations. Colorado's Lawful Off-Duty Activities Statute, C.R.S. § 24-34-402.5, protects employees from termination for lawful off-duty conduct, but courts have held this does not apply to marijuana use by DOT-regulated employees. In Coats v. Dish Network (2015), the Colorado Supreme Court ruled that marijuana use is not "lawful" under the statute because it violates federal law.

Washington

Washington legalized recreational cannabis in 2012. The state employs approximately 320,000 DOT-regulated workers, including significant maritime and aviation sectors. Washington's Initiative 502 explicitly states that employers may prohibit marijuana use and that nothing in the law requires accommodation of marijuana use. Washington courts have consistently upheld employer rights to terminate for marijuana use in safety-sensitive positions.

New York

New York legalized recreational cannabis in 2021 through the Marijuana Regulation and Taxation Act. The law prohibits employment discrimination based on cannabis use outside the workplace, but explicitly exempts positions where federal law requires testing. Approximately 875,000 New Yorkers work in DOT-regulated positions. New York Labor Law § 201-d(4-a) states that protections do not apply when the employer would violate federal law or lose federal contracts or funding.

Florida

Florida has medical marijuana only, authorized by constitutional amendment in 2016. The state employs approximately 950,000 DOT-regulated workers, including significant numbers in aviation, maritime, and trucking. Florida Statute § 381.986(15) explicitly states that medical marijuana law does not require accommodation of medical marijuana use in the workplace or limit employer rights to enforce drug-free workplace policies.

Texas

Texas maintains restrictive cannabis laws with limited low-THC medical cannabis access. The state employs approximately 1.1 million DOT-regulated workers, particularly in trucking and pipeline sectors. Texas has no state-level employment protections for cannabis use. Texas employers in transportation sectors report lower rates of failed drug tests compared to legalization states, according to 2025 Quest Diagnostics data.

Illinois

Illinois legalized recreational cannabis in 2020. The Cannabis Regulation and Tax Act prohibits employment discrimination but exempts positions where federal law requires testing. Approximately 485,000 Illinois residents work in DOT-regulated positions. Illinois courts have held that the Act's employment protections do not apply to federally regulated transportation workers.

Michigan

Michigan legalized recreational cannabis in 2018. The state employs approximately 425,000 DOT-regulated workers. Michigan's Regulation and Taxation of Marihuana Act explicitly states that employers may discipline employees for marijuana use and that the Act does not limit employer rights to enforce workplace drug policies. Michigan courts have upheld terminations of DOT-regulated employees for marijuana use.

Ohio

Ohio voters approved recreational cannabis legalization in November 2023, with sales beginning in 2024. The state employs approximately 520,000 DOT-regulated workers. Ohio's legalization statute includes employment protections but exempts positions where federal law requires drug testing. Ohio employers report increased complexity in managing DOT compliance alongside state legalization.

Massachusetts

Massachusetts legalized recreational cannabis in 2016. The state employs approximately 295,000 DOT-regulated workers. Massachusetts law prohibits employment discrimination for off-duty marijuana use, but courts have held this does not apply to federally regulated positions. In Barbuto v. Advantage Sales and Marketing (2017), the Massachusetts Supreme Judicial Court held that employers must engage in interactive process for medical marijuana accommodation, but this ruling does not apply to DOT-regulated positions where federal law prohibits accommodation.

Market and Business Implications

DOT cannabis testing policy creates significant operational costs, workforce challenges, and competitive dynamics across the $1.5 trillion transportation sector. The American Trucking Associations estimates that failed drug tests cost the industry $2.8 billion annually in recruitment, training, and lost productivity. With 50,000 CDL applicants failing pre-employment screens each year and marijuana accounting for 60% of failures, the policy directly contributes to the driver shortage crisis affecting supply chain efficiency. Testing costs average $45-65 per urine specimen for DOT-compliant testing, including collection, laboratory analysis, and Medical Review Officer review. A motor carrier with 1,000 drivers conducting random testing at 50% annual rate spends approximately $27,500 annually on random testing alone, plus pre-employment, post-accident, reasonable suspicion, and return-to-duty testing. The Drug and Alcohol Clearinghouse imposes additional costs. Employers must query the Clearinghouse for all CDL drivers annually at $1.25 per query, plus $1.25 for pre-employment full queries. A large carrier with 10,000 drivers spends $12,500 annually on Clearinghouse queries alone. Return-to-duty processes are expensive. A driver who tests positive must complete Substance Abuse Professional evaluation ($400-800), follow recommended treatment (costs vary widely), pass return-to-duty test ($65), and undergo minimum six follow-up tests over 12 months ($390). Total return-to-duty costs typically range from $2,000 to $10,000 per driver. Insurance implications are substantial. Commercial auto insurers consider drug testing program quality in underwriting. Carriers with higher-than-average positive test rates face premium increases. Nuclear verdicts in trucking accidents increasingly examine driver drug testing history, with plaintiffs arguing that positive marijuana tests indicate negligent hiring or retention. Workforce composition effects are significant. Transportation employers in legalization states report difficulty recruiting younger workers who use cannabis recreationally. A 2025 American Transportation Research Institute survey found that 38% of carriers in legalization states reported increased recruitment challenges attributed to cannabis policy conflicts. Multi-state operators face compliance complexity. A trucking company operating in 38 states must maintain uniform DOT testing while navigating varying state employment laws, workers' compensation rules, and unemployment insurance determinations. Legal costs for policy development and defense average $50,000-150,000 annually for mid-sized carriers. Technology investments are increasing. Employers are adopting electronic chain-of-custody systems, automated Clearinghouse query processes, and digital Medical Review Officer platforms. The DOT drug testing technology market reached $485 million in 2025, growing at 7.2% annually according to industry analysis. Alternative testing methods represent potential market disruption. Oral fluid testing, approved by DOT in 2023 for certain circumstances, costs $75-95 per test but offers observed collection without privacy concerns of urine testing. Hair testing, not currently DOT-approved, detects longer windows of drug use but costs $125-175 per test. Cannabis industry implications are complex. State-legal cannabis operators cannot employ DOT-regulated drivers or pilots who use their products. Vertical integration strategies in cannabis must exclude transportation components requiring CDL drivers. Cannabis delivery services use non-CDL vehicles to avoid DOT testing requirements, limiting delivery capacity and efficiency. Capital markets impact is emerging. Transportation companies face investor questions about cannabis policy risks. Trucking companies with high driver turnover attributed to failed drug tests trade at valuation discounts. Conversely, drug testing service providers have attracted private equity investment, with Quest Diagnostics' employer solutions segment growing revenue 12% in 2025.

What Experts Say

Transportation safety professionals, medical experts, and policy analysts offer sharply divergent views on whether current DOT cannabis testing policy serves its intended safety goals. According to the Commercial Vehicle Safety Alliance, which represents enforcement officials across North America, marijuana impairment poses significant highway safety risks that justify continued testing. CVSA President Capt. John Samis stated in 2025 Congressional testimony that "marijuana affects reaction time, lane tracking, and cognitive function—all critical to safe vehicle operation." The National Transportation Safety Board, which investigates major transportation accidents, has documented marijuana involvement in numerous fatal crashes. NTSB Chair Jennifer Homendy said in a 2024 safety recommendation letter that "post-accident toxicology consistently reveals marijuana presence in operators involved in fatal accidents, supporting continued testing requirements." Medical experts offer more nuanced perspectives. Dr. Marilyn Huestis, a leading cannabis pharmacology researcher, notes that current DOT testing detects inactive THC metabolites that persist long after impairment ends. According to Dr. Huestis, "THC-COOH can be detected for weeks in regular users, but impairment lasts only 3-4 hours after inhalation." She advocates for impairment-based testing rather than metabolite detection. The American College of Occupational and Environmental Medicine published a 2020 position statement acknowledging that "cannabis metabolite testing does not measure current impairment" but supporting testing as part of comprehensive workplace safety programs. ACOEM emphasizes that employers should focus on fitness-for-duty rather than off-duty conduct. Labor economists point to workforce impacts. Dr. Angela Dills, an economist at Western Carolina University who studies cannabis policy, found in 2024 research that DOT testing requirements reduce labor force participation in legalization states by approximately 2.3% among potential commercial drivers. According to Dr. Dills, "the policy creates a mismatch between state-legal conduct and federal employment requirements." Transportation industry executives emphasize liability concerns. Derek Leathers, CEO of Werner Enterprises, stated in a 2025 earnings call that "we cannot compromise on DOT testing compliance regardless of state laws—our liability exposure in accidents is too significant." He noted that plaintiff attorneys increasingly use marijuana testing history in litigation. Drug policy reform advocates argue the policy is counterproductive. According to Paul Armentano of NORML, "DOT testing disqualifies safe operators based on off-duty conduct while failing to identify actually impaired drivers." He advocates for cognitive impairment testing using technology that measures reaction time and decision-making rather than detecting drug metabolites. Toxicologists highlight testing limitations. Dr. Barry Sample, senior science consultant at Quest Diagnostics, notes that "urine testing is the gold standard for detecting drug use, but it does not measure impairment or predict safety risk." He supports development of oral fluid testing and point-of-collection testing technology to reduce detection windows. Legal scholars examine constitutional dimensions. Professor Alex Kreit of Thomas Jefferson School of Law argues that DOT testing of off-duty marijuana use in legalization states raises Fourth Amendment questions. According to Professor Kreit, "suspicionless drug testing is constitutionally permissible in safety-sensitive positions, but the rationale weakens when testing detects conduct that is legal under state law and occurred days or weeks before testing." Public health researchers study population-level effects. Dr. Julian Santaella-Tenorio of Columbia University found in 2023 research that commercial vehicle accident rates did not increase in states after marijuana legalization, suggesting that DOT testing may be preventing cannabis-using individuals from entering transportation professions rather than preventing impaired operation.

What's Next

DOT cannabis testing policy faces multiple decision points in 2026-2027 that could maintain, modify, or fundamentally restructure the current framework. The most immediate catalyst is DEA's marijuana rescheduling decision. DEA Administrator Anne Milgram must issue a final rule on the Schedule III proposal by August 2026 under Administrative Procedure Act timelines. If marijuana moves to Schedule III, DOT must determine whether to maintain marijuana on the testing panel. While DOT has indicated that rescheduling would not automatically change testing requirements, pressure from industry and reform advocates would intensify. Congressional action represents another pathway. Senator Cory Booker and Representative Earl Blumenauer introduced the Marijuana Opportunity Reinvestment and Expungement Act in 2025, which includes provisions directing DOT to study impairment-based testing alternatives. The bill has 87 House cosponsors as of May 2026 but faces uncertain prospects in a divided Congress. Appropriations riders could also affect DOT testing policy. Oral fluid testing expansion is proceeding. DOT approved oral fluid testing for certain circumstances in 2023 regulations but has not authorized full substitution for urine testing. The agency is evaluating oral fluid testing data from early adopters. Full authorization could come in late 2026 or 2027. Oral fluid testing detects THC for 12-24 hours after use rather than weeks, potentially reducing conflicts between off-duty cannabis use and employment. Technology development continues. Multiple companies are developing roadside impairment testing devices using cognitive assessment, eye tracking, and physiological measures. Druid app, developed by Massachusetts General Hospital researchers, measures impairment through smartphone-based cognitive tests. If validated for DOT use, such technology could shift policy from drug detection to actual impairment assessment. Litigation is ongoing. Multiple lawsuits challenge DOT testing requirements as applied to state-legal medical marijuana patients. In Noffsinger v. SSA Cooper (pending in Colorado federal court), a truck driver argues that termination for medical marijuana use violates the Americans with Disabilities Act. While precedent favors employers, circuit splits could lead to Supreme Court review. State legislative activity is accelerating. New York, New Jersey, and Connecticut have enacted employment protections for off-duty cannabis use with exemptions for federal requirements. If additional states adopt similar laws, pressure on DOT to reconsider policy will increase. State attorneys general could also challenge DOT regulations as exceeding statutory authority. Industry pressure is building. The American Trucking Associations, historically supportive of DOT testing, established a task force in 2025 to study alternative approaches to cannabis policy. The task force is examining whether modified testing protocols could address driver shortage concerns while maintaining safety. Recommendations are expected in late 2026. The Federal Motor Carrier Safety Administration is conducting a study on marijuana and highway safety, mandated by the Infrastructure Investment and Jobs Act of 2021. The study examines crash causation data, impairment research, and testing alternatives. Results are due to Congress in September 2026 and could inform policy changes. International developments may influence U.S. policy. Canada legalized recreational cannabis in 2018 but maintains workplace testing for safety-sensitive positions. Canadian courts have developed a framework requiring employers to demonstrate that testing is rationally connected to job performance. U.S. courts could adopt similar analysis. The 2026 election cycle will shape cannabis policy broadly. If the administration changes in January 2027, DOT leadership could shift approaches. However, civil service protections and regulatory process requirements mean that significant policy changes would require formal rulemaking taking 18-24 months minimum. Economic pressure from the driver shortage may force action. If the trucking industry shortage reaches 100,000 drivers by 2027 as projected, Congress may direct DOT to implement emergency measures. Temporary waivers or modified testing protocols could be authorized.

Further Reading

• 49 CFR Part 40 – DOT Procedures for Transportation Workplace Drug and Alcohol Testing Programs (full regulatory text): https://www.ecfr.gov/current/title-49/subtitle-A/part-40
• DOT Office of Drug and Alcohol Policy and Compliance official guidance: https://www.transportation.gov/odapc
• Federal Motor Carrier Safety Administration Drug and Alcohol Clearinghouse: https://clearinghouse.fmcsa.dot.gov/
• DEA Notice of Proposed Rulemaking on Marijuana Rescheduling (May 16, 2024): https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• National Transportation Safety Board Safety Recommendation Database (marijuana-related): https://www.ntsb.gov/safety/safety-recs/
• Quest Diagnostics Drug Testing Index (annual workplace drug testing data): https://www.questdiagnostics.com/dti
• American Trucking Associations Driver Shortage Analysis: https://www.trucking.org/economics-and-industry-data
• Omnibus Transportation Employee Testing Act of 1991, 49 U.S.C. § 31306: https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title49-section31306
• NORML Workplace Drug Testing Position Paper: https://norml.org/marijuana/fact-sheets/workplace-drug-testing/
• Federal Aviation Administration Drug and Alcohol Testing Program: https://www.faa.gov/about/office_org/headquarters_offices/avs/offices/aam/drug_alcohol/
• Congressional Research Service Report: Marijuana Use and Federal Drug Testing Programs (updated 2025): https://crsreports.congress.gov
• National Institute on Drug Abuse Research on Cannabis and Driving: https://nida.nih.gov/research-topics/cannabis-marijuana/driving